文献速递银屑病与炎症性皮肤病

银屑病免疫-表皮双重靶向:新兴技术与转化治疗策略

Immune-Epidermal Dual Targeting in Psoriasis: Emerging Technologies and Translational Therapeutic Strategies.
PubMed 文献 · Br J Dermatol · 2026-09-08

本综述从环路和网络视角整合免疫驱动炎症与表皮放大机制,提出以免疫细胞与角质形成细胞促炎反馈为核心的免疫-表皮双重靶向框架,并总结联合治疗、单药双重靶向及阻断桥接节点三条实施路径,同时讨论人工智能、多组学、类器官及精准局部递送在靶点发现与治疗转化中的潜在作用与边界。

要点

  • 免疫靶向治疗虽改善银屑病短期控制,但部分患者应答不足且停药后复发仍待解决。
  • 提出免疫-表皮双重靶向框架,聚焦免疫细胞与角质形成细胞间促炎反馈环路。
  • 实现路径包括联合治疗、单药双重靶向和阻断免疫-表皮反馈中的桥接节点。

核心结论

  • 免疫-表皮双重靶向框架不替代现有治疗范式,而是完善其机制解读并拓展未来治疗策略。
  • 该框架可能为银屑病分层、分期和精准管理提供额外转化机会,但部分组件仍处于机制研究和临床验证阶段。

研究设计与样本

  • 综述整合免疫驱动炎症与表皮放大机制,从环路和网络视角提出免疫-表皮双重靶向框架。

主要发现

  • 免疫靶向治疗(尤其靶向IL-23/IL-17轴)显著改善银屑病短期疾病控制,但部分患者应答不足且停药后复发。
  • 免疫中心治疗可能未充分解决表皮角质形成细胞对炎症放大和疾病持续的作用。

关键数值与推荐

  • 系统总结三条潜在实施路径:联合治疗、单药双重靶向、阻断免疫-表皮反馈环路中的桥接节点。
  • 讨论人工智能与多组学分析、类器官与工程皮肤模型、精准局部递送技术在靶点发现、机制验证和治疗转化中的潜在作用与边界。

临床怎么用

  • 临床可关注免疫-表皮双重靶向框架,为银屑病分层、分期和精准管理提供思路,但需注意部分组件尚待临床验证。

局限性

  • 框架中多个组件仍处于机制研究和临床验证阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although immune-targeted therapies, particularly agents targeting the IL-23/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centered therapies may not fully address the active contribution of epidermal keratinocytes (KCs) to inflammatory amplification and disease persistence. In this review, we integrate immune-driven inflammation and epidermal amplification mechanisms from a loop- and network-based perspective, and propose an immune-epidermal dual-targeting framework centred on pro-inflammatory feedback between immune cells and KCs. We systematically summarize three potential implementation routes: combination therapy, single-agent dual targeting and blockade of bridging nodes within immune-epidermal feedback circuits. We further discuss the potential roles and realistic boundaries of artificial intelligence and multi-omics analysis, organoids and engineered skin models, and precision local delivery technologies in target discovery, mechanistic validation and therapeutic translation. Importantly, this framework is not intended to replace existing therapeutic paradigms, but rather to refine their mechanistic interpretation and extend future therapeutic strategies. It may provide additional translational opportunities for stratified, stage-specific and precision management of psoriasis, although several components remain at the stage of mechanistic research and clinical validation.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu M, Dong P, Yang C, et al. Immune-Epidermal Dual Targeting in Psoriasis: Emerging Technologies and Translational Therapeutic Strategies. Br J Dermatol. 2026. PMID: 42706986. doi:10.1093/bjd/ljag390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。